JP2013511552A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511552A5 JP2013511552A5 JP2012540139A JP2012540139A JP2013511552A5 JP 2013511552 A5 JP2013511552 A5 JP 2013511552A5 JP 2012540139 A JP2012540139 A JP 2012540139A JP 2012540139 A JP2012540139 A JP 2012540139A JP 2013511552 A5 JP2013511552 A5 JP 2013511552A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- poxvirus
- subject
- peptide
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 238000000034 method Methods 0.000 claims 8
- 241000700618 Vaccinia virus Species 0.000 claims 6
- 230000028993 immune response Effects 0.000 claims 6
- 230000001939 inductive effect Effects 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 5
- 206010022000 influenza Diseases 0.000 claims 5
- 230000028327 secretion Effects 0.000 claims 5
- 101710154606 Hemagglutinin Proteins 0.000 claims 4
- 102000011931 Nucleoproteins Human genes 0.000 claims 4
- 108010061100 Nucleoproteins Proteins 0.000 claims 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims 4
- 101710176177 Protein A56 Proteins 0.000 claims 4
- 230000002238 attenuated effect Effects 0.000 claims 4
- 239000000185 hemagglutinin Substances 0.000 claims 4
- 229960005486 vaccine Drugs 0.000 claims 4
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 208000007089 vaccinia Diseases 0.000 claims 3
- 102000005348 Neuraminidase Human genes 0.000 claims 2
- 108010006232 Neuraminidase Proteins 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 241000712461 unidentified influenza virus Species 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26332709P | 2009-11-20 | 2009-11-20 | |
| US61/263,327 | 2009-11-20 | ||
| PCT/US2010/057682 WO2011063359A1 (en) | 2009-11-20 | 2010-11-22 | Compositions, methods and uses for poxvirus elements in vaccine constructs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013511552A JP2013511552A (ja) | 2013-04-04 |
| JP2013511552A5 true JP2013511552A5 (enExample) | 2014-01-16 |
| JP5798124B2 JP5798124B2 (ja) | 2015-10-21 |
Family
ID=44060068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012540139A Expired - Fee Related JP5798124B2 (ja) | 2009-11-20 | 2010-11-22 | ワクチン構築物におけるポックスウイルスエレメントに関する免疫原性組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9011874B2 (enExample) |
| EP (1) | EP2501405A4 (enExample) |
| JP (1) | JP5798124B2 (enExample) |
| AU (1) | AU2010321731B2 (enExample) |
| CA (1) | CA2781397A1 (enExample) |
| WO (1) | WO2011063359A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9005632B2 (en) * | 2009-11-20 | 2015-04-14 | Takeda Vaccines, Inc. | Compositions, methods and uses for poxvirus elements in vaccine constructs against influenza virus subtypes or strains |
| EP3197490B1 (en) * | 2014-09-26 | 2023-06-21 | Bavarian Nordic A/S | Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| WO1997027216A1 (en) * | 1996-01-29 | 1997-07-31 | Georgetown University | Amplification of response from expressed recombinant protein |
| NZ521270A (en) * | 2000-03-14 | 2003-06-30 | Bavarian Nordic As | Altered strain of the Modified Vaccinia virus Ankara (MVA) for growth in a continuous vero cell line |
| DE20122302U1 (de) * | 2000-11-23 | 2005-02-24 | Bavarian Nordic A/S | Variante des Modifizierten Vaccinia-Ankara-Virus |
| AU2003258168B2 (en) * | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| EP1928916A2 (en) * | 2005-09-29 | 2008-06-11 | Viral Logic Systems Technology Corp. | Immunomodulatory compositions and uses therefor |
| CA2657849A1 (en) * | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| US7910112B2 (en) * | 2006-11-06 | 2011-03-22 | Merial Limited | Feline vaccines against avian influenza |
| EP1925318A1 (en) | 2006-11-20 | 2008-05-28 | Paul-Ehrlich-Institut | Recombinant modified vaccinia virus Ankara (MVA)-based vaccine for the avian flu |
| EP2167123A4 (en) * | 2007-07-09 | 2012-09-05 | Usa As Represented By The Secretary Of The Army On Behalf Of The United States Army Medical Res | COMPOSITIONS CONTAINING L1R ENUCTIVE NUCLEIC ACID AND ENDOPLASMIC RETICULUM TARGETING SEQUENCE |
| US7807180B2 (en) * | 2007-08-21 | 2010-10-05 | University Of Massachusetts | Poxvirus methods and compositions |
-
2010
- 2010-11-22 WO PCT/US2010/057682 patent/WO2011063359A1/en not_active Ceased
- 2010-11-22 JP JP2012540139A patent/JP5798124B2/ja not_active Expired - Fee Related
- 2010-11-22 US US13/510,601 patent/US9011874B2/en not_active Expired - Fee Related
- 2010-11-22 CA CA2781397A patent/CA2781397A1/en not_active Abandoned
- 2010-11-22 EP EP10832340.3A patent/EP2501405A4/en not_active Withdrawn
- 2010-11-22 AU AU2010321731A patent/AU2010321731B2/en not_active Ceased
-
2015
- 2015-03-11 US US14/645,269 patent/US20150184198A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11103578B2 (en) | Respiratory virus nucleic acid vaccines | |
| Stachyra et al. | DNA vaccines against influenza. | |
| JP2008530245A5 (enExample) | ||
| Bezbaruah et al. | Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19 | |
| JP2010500399A5 (enExample) | ||
| CN101636177A (zh) | 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗 | |
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| JP2012515557A5 (enExample) | ||
| RU2015132962A (ru) | Иммуногенные композиции на основе вируса гриппа и их применение | |
| JP2013523096A (ja) | インフルエンザマトリックス２タンパク質の外部ドメイン、発現システムおよびそれらの使用 | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2014503206A5 (enExample) | ||
| IL276210B2 (en) | Mers-cov vaccine | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| CN104780937A (zh) | 涉及由多核苷酸编码的免疫原性多肽的新型初免-加强方案 | |
| JP2009504654A5 (enExample) | ||
| JP2014507146A5 (enExample) | ||
| JP2010508030A5 (enExample) | ||
| JP2013523096A5 (enExample) | ||
| JP2011517938A5 (enExample) | ||
| JP2010506926A5 (enExample) | ||
| JP2019505567A5 (enExample) | ||
| JP2018501258A5 (enExample) | ||
| US20230210980A1 (en) | Chimeric adenoviral vectors | |
| JP2020515283A5 (enExample) |